Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US initial public offering, priced at the top of a marketed range.
Science Bloomberg Jul 31, 2026
Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US initial public offering, priced at the top of a marketed range.
